Rapid generation of a well-matched vaccine seed from a modern influenza A virus primary isolate without recourse to eggs

Vaccine

Volumn 28, Issue 17, 2010, Pages 2973-2979

  Hartgroves, L C S ^a   Koudstaal, W ^b   McLeod, C ^a   Moncorge O ^a   Thompson, C I ^c   Ellis, J ^c   Bull, C ^d   Havenga, M J E ^e   Goudsmit, J ^b   Barclay, W S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CRUCELL HOLLAND BV   (Netherlands)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e TNO   (Netherlands)

Author keywords

Influenza; Reverse genetics; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ANIMAL CELL; ARTICLE; GENE MUTATION; HUMAN; HUMAN CELL; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H3N2; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS GENE; VIRUS MUTATION;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; RECOMBINATION, GENETIC; VIRUS CULTIVATION;

EID: 77949655878     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.012     Document Type: Article

References (35)

1. Medeiros R., Escriou N., Naffakh N., Manuguerra J., and van der Werf S. Hemagglutinin residues of recent human A(H3N2) influenza viruses that contribute to the inability to agglutinate chicken erythrocytes. Virology 289 1 (2001) 74
2. Mochalova L., Gambaryan A., Romanova J., Tuzikov A., Chinarev A., Katinger D., et al. Receptor-binding properties of modern human influenza viruses primarily isolated in Vero and MDCK cells and chicken embryonated eggs. Virology 313 2 (2003) 473
3. Thompson C., Barclay W., and Zambon M. Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host. J Antimicrob Chemother 53 5 (2004) 759-765
4. Schild G., Oxford J., de Jong J., and Webster R. Evidence for host-cell selection of influenza virus antigenic variants. Nature 303 5919 (1983) 706-709
5. Chen Z., Aspelund A., and Jin H. Stabilizing the glycosylation pattern of influenza B hemagglutinin following adaptation to growth in eggs. Vaccine 26 3 (2008) 361-371
6. Kodihalli S., Justewicz D., Gubareva L., and Webster R. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. J Virol 69 8 (1995) 4888-4897
7. Lu B., Zhou H., Ye D., Kemble G., and Jin H. Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities. Using reverse genetics. J Virol 79 11 (2005) 6763-6771
8. Lu B., Zhou H., Chan W., Kemble G., and Jin H. Single amino acid substitutions in the hemagglutinin of influenza A/Singapore/21/04 (H3N2) increase virus growth in embryonated chicken eggs. Vaccine 24 44-46 (2006) 6691
9. Halperin S., Nestruck A., and Eastwood B. Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine 16 13 (1998) 1331
10. Kistner O., Barrett P., Mundt W., Reiter M., Schober-Bendixen S., and Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16 9-10 (1998) 960-968
11. Brands R., Visser J., Medema J., Palache A., and van Scharrenburg G. Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. Dev Biol Stand 98 (1999) 93-100 [discussion 111]
12. Pau M., Ophorst C., Koldijk M., Schouten G., Mehtali M., and Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 19 17-19 (2001) 2716-2721
13. Audsley J., and Tannock G. The growth of attenuated influenza vaccine donor strains in continuous cell lines. J Virol Methods 123 2 (2005) 187
14. Minor P., Engelhardt O., Wood J.M., Robertson J.S., Blayer S., Colegate T., et al. Current challenges in implementing cell-derived influenza vaccines: Implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 27 22 (2009) 2907-2913
15. Fodor E., Devenish L., Engelhardt O., Palese P., Brownlee G., and Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 73 11 (1999) 9679-9682
16. Neumann G., Watanabe T., Ito H., Watanabe S., Goto H., Gao P., et al. Generation of influenza A viruses entirely from cloned cDNAs. PNAS 96 16 (1999) 9345-9350
17. Stieneke-Grober A., Vey M., Angliker H., Shaw E., Thomas G., Roberts C., et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 11 7 (1992) 2407-2414
18. Li S., Liu C., Klimov A., Subbarao K., Perdue M., Mo D., et al. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis 179 5 (1999) 1132-1138
19. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305 1 (2003) 192
20. Stech J., Garn H., Wegmann M., Wagner R., and Klenk H.D. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat Med 11 6 (2005) 683-689 Epub 2005 May 2029
21. Horimoto T., Takada A., Fujii K., Goto H., Hatta M., Watanabe S., et al. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24 17 (2006) 3669-3676 Epub 2005 Jul 3621
22. ® cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine 27 19 (2009) 2588-2593
23. Matrosovich M., Matrosovich T., Carr J., Roberts N., and Klenk H.D. Overexpression of the {alpha}-2,6-Sialyltransferase in MDCK Cells Increases Influenza Virus Sensitivity to Neuraminidase Inhibitors. J Virol 77 15 (2003) 8418-8425
24. Hayman A., Comely S., Lackenby A., Murphy S., McCauley J., Goodbourn S., et al. NS1 proteins of avian influenza A viruses can act as antagonists of the human alpha/beta interferon response. J Virol 81 5 (2007) 2318-2327 Epub 2006 Dec 2320
25. Whiteley A., Major D., Legastelois I., Campitelli, Donatelli I., Thompson C., et al. Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat. Influenza Other Respir Viruses 1 4 (2007) 157-166
26. Oh D., Barr I., Mosse J., and Laurie K. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J Clin Microbiol 46 7 (2008) 2189-2194
27. Kumari K., Gulati S., Smith D., Gulati U., Cummings R., and Air G. Receptor binding specificity of recent human H3N2 influenza viruses. Virol J 4 1 (2007) 42
28. Mitnaul L., Matrosovich M., Castrucci M., Tuzikov A., Bovin N., Kobasa D., et al. Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J Virol 74 13 (2000) 6015-6020
29. Wagner R., Matrosovich M., and Klenk H.D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol 12 3 (2002) 159-166
30. Treanor J., Wilkinson B., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 13-14 (2001) 1732
31. Wang K., Holtz K., Anderson K., Chubet R., Mahmoud W., Cox M., et al. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 24 12 (2006) 2176
32. Huber V., and McCullers J. FluBlok, a recombinant influenza vaccine. Curr Opin Mol Ther 10 1 (2008) 75-85
33. Horimoto T., Murakami S., Muramoto Y., Yamada S., Fujii K., Kiso M., et al. Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology 366 1 (2007) 23-27
34. Garcia J.-M., Pepin S., Lagarde N., Ma E., Vogel F., Chan K., et al. Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS One 4 11 (2009) e7918
35. Sandbulte M., Jimenez G., Boon A., Smith L., Treanor J., and Webby R. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4 2 (2007) e59